FDA Research Developing Bioassays Using Ovarian Cancer Cells

How to Apply

To submit your application, scroll to the bottom of this opportunity and click APPLY.

• An application
• Transcripts –  for detailed information about acceptable transcripts
• A current resume/CV, including academic history, employment history, relevant experiences, and publication list
• One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.OC.other. Please include the reference code for this opportunity in your email.

Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!

U.S. Food and Drug Administration (FDA)

FDA-OWH-

5/15/2026 3:00:00 PM Eastern Time Zone

Applications will be reviewed on a rolling basis.

A Postdoctoral Fellow opportunity is available with Dr. Wen Jin Wu and located at Division of Pharmaceutical Quality Research III (DPQR III), Office of Pharmaceutical Quality Research (OPQR), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER) in Silver Spring, Maryland. Funding for this opportunity will be provided by the Office of Commissioner (OC), Office of Women’s Health (OWH).

Under the guidance of the mentor, the participant will study trispecific antibodies using women breast and ovarian cancers and animal models to improve FDA-regulated product quality, safety, and anti-tumor activity and to facilitate drug development to treat women’s cancers.

• Develop an understanding of antibody therapeutic concepts, including the principles of bispecific and trispecific antibodies
• Learn how to design different molecular formats for bispecific and trispecific antibodies using genetic engineering approaches, applying appropriate structural and functional considerations
• Learn how to carry out experiments for the expression and production of bispecific and trispecific antibodies using established laboratory methods
• Gain experience in performing comprehensive characterization studies of bispecific and trispecific antibodies including:
• • Physicochemical analysis
  • Biological activity assessment
  • Mechanism of action investigations
  • Bioassay development
• Apply acquired knowledge to support ongoing research projects and regulatory mission, and advance their professional development in antibody therapeutics

The mentor for this opportunity is Dr. Wen Jin Wu (wen.wu.gov). If you have questions about the nature of the research, please contact the mentor.

Anticipated Appointment

Start Date:

2026. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

Participant Stipend: The participant will receive a monthly stipend commensurate with educational level and experience.

This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for…